{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:50:37Z","timestamp":1777438237428,"version":"3.51.4"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The purpose of this study is to review the neonatal and early childhood course of children who were treated with intravitreal bevacizumab for APROP and identify any long term limitations these children face years after treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective consecutive case series reviewed both ophthalmologic and pediatric medical records to determine ocular and neurologic function following treatment with a single injection of intravitreal bevacizumab (IVB) for APROP. Patient records were reviewed to identify the gestational age, average birth weight, gender, post-menstrual age (PMA) at the time of injection, regression status, rescue therapy events, final visual acuity, final refraction, ophthalmologic diagnoses and complications, neurologic diagnoses, and duration of follow up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 43 eyes from 13 male and 9 female children. The average gestational age was 24 weeks and average birth weight was 625.2 grams. The average follow-up was 4.08 years (range: 1.85\u20137.36 years). The average PMA at time of bevacizumab injection was 35.59 weeks. Thirty-five eyes eventually received laser photocoagulation at an average PMA of 53.17 weeks. All eyes in this study demonstrated regression without progression to retinal detachment. At last follow up, 67% (29\/43) of eyes were able to discern letters or shapes, with an average visual acuity of 20\/37. 16 (72%) children were diagnosed with perinatal neurological disorders. 59% (<jats:italic>n<\/jats:italic> = 13) developed chronic neurological impairment, 77% (<jats:italic>n<\/jats:italic> = 10) of whom developed neurodevelopmental delay. Several infants were diagnosed with endocrine disease or genetic syndromes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Extreme prematurity is associated with significant morbidity. Nearly all infants (92%) who developed chronic neurologic disease were diagnosed with neurologic disease during the perinatal period. Intravitreal bevacizumab, often with adjuvant photocoagulation, led to regression without detachment in 100% of eyes, with most verbal children retaining functional vision.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.778585","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T05:59:52Z","timestamp":1644559192000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Aggressive Posterior Retinopathy of Prematurity: Long-Term Outcomes Following Intravitreal Bevacizumab"],"prefix":"10.3389","volume":"10","author":[{"given":"Ameay V.","family":"Naravane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Belin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaina","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Polly A.","family":"Quiram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1177\/1120672119827773","article-title":"The use of bevacizumab in pediatric retinal and choroidal disease: a review","volume":"29","author":"Belin","year":"2019","journal-title":"Eur J Ophthalmol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/APO.0000000000000302","article-title":"Update on anti-vascular endothelial growth factor safety for retinopathy of prematurity","volume":"9","author":"Enriquez","year":"2020","journal-title":"Asia Pac J Ophthalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"International committee for the classification of retinopathy of prematurity. The international classification of retinopathy of prematurity revisited","volume":"123","author":"Gole","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1159\/000478694","article-title":"Aggressive posterior retinopathy of prematurity in a premature male infant","volume":"8","author":"Zhou","year":"2017","journal-title":"Case Rep Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1097\/IAE.0b013e3181cb6151","article-title":"Aggressive posterior retinopathy of prematurity","volume":"30","author":"Dresner","year":"2010","journal-title":"Retina."},{"key":"B6","first-page":"233","article-title":"Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"B7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity to RD in AP ROP","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the american academy of ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1755-3768.2011.02351.x","article-title":"Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?","volume":"91","author":"Spandau","year":"2013","journal-title":"Acta Ophthalmologica."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.12659\/MSM.897095","article-title":"Regression rates following the treatment of aggressive posterior retinopathy of prematurity with bev- acizumab versus laser: 8-year retrospective analysis","volume":"22","author":"Nicoar\u01ce","year":"2016","journal-title":"Med Sci Monit Int Med J Exp Clin Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/IAE.0000000000002943","article-title":"Outcomes of nonconfluent diode laser panretinal photocoagulation for aggressive posterior retinopathy of prematurity after intravitreal bevacizumab","volume":"41","author":"Mammo","year":"2021","journal-title":"Retina."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3928\/01913913-20210316-01","article-title":"Comparison of outcomes between combined laser photocoagulation and intravitreal bevacizumab treatment versus conventional laser photocoagulation in aggressive posterior retinopathy of prematurity","volume":"20","author":"Ittarat","year":"2020","journal-title":"J Pediatric Ophthalmol Strabismus."},{"key":"B13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4103\/0974-620X.142592","article-title":"Long term refractive and structural outcome following laser treatment for zone 1 aggressive posterior retinopathy of prematurity","volume":"7","author":"Shah","year":"2014","journal-title":"Oman J Ophthalmol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/ceo.12280","article-title":"Prevalence and outcomes of laser treatment of aggressive posterior retinopathy of prematurity","volume":"42","author":"Gunn","year":"2014","journal-title":"Clin Exp Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jaapos.2019.05.014","article-title":"Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India: implications for primary, secondary, and tertiary prevention","volume":"23","author":"Shah","year":"2019","journal-title":"J AAPOS."},{"key":"B16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3928\/01913913-20150216-01","article-title":"Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years","volume":"52","author":"Klufas","year":"2015","journal-title":"J Pediatric Ophthalmol Strabismus."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/s41433-021-01392-6","article-title":"Aggressive posterior retinopathy of prematurity: a review on current understanding","volume":"35","author":"Kumawat","year":"2021","journal-title":"Eye."},{"key":"B18","unstructured":"Drug Safety Communication. FDA Reviews Results in New Warnings About Using General Anesthetics and Sedation Drugs in Young Children and Pregnant Women"},{"key":"B19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3928\/23258160-20190605-01","article-title":"Neurodevelopmental outcomes comparing bevacizumab to laser for type 1 ROP","volume":"50","author":"Rodriguez","year":"2019","journal-title":"Ophthalmic Surg Lasers Imag Retin."},{"key":"B20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jaapos.2012.10.011","article-title":"Incidence of cataract development by 6 months' corrected age in the early treatment for retinopathy of prematurity study","volume":"17","author":"Davitt","year":"2013","journal-title":"J AAPOS."},{"key":"B21","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/aos.14354","article-title":"Prevalence and causes of infantile nystagmus in a large population-based danish cohort","volume":"98","author":"Hvid","year":"2020","journal-title":"Acta Ophthalmol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"679546","DOI":"10.3389\/fped.2021.679546","article-title":"Severe retinopathy of prematurity is not independently associated with worse neurodevelopmental outcomes in preterm neonates","volume":"9","author":"Altendahl","year":"2021","journal-title":"Front Pediatri."},{"key":"B23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.5935\/0004-2749.20150079","article-title":"Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity","volume":"78","author":"Gunay","year":"2015","journal-title":"Arq Bras Oftalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ajoc.2018.05.006","article-title":"Favorable outcomes of adequate laser photocoagulation and salvage bevacizumab treatment for aggressive posterior retinopathy of prematurity","volume":"11","author":"Fukushima","year":"2018","journal-title":"Am J Ophthalmol Case Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum vegf and igf-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS ONE."},{"key":"B29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3928\/23258160-20200831-02","article-title":"Two-year outcomes comparing anti-VEGF injections to laser for ROP using a commercial claims database","volume":"51","author":"Zhang","year":"2020","journal-title":"OSLI Retina."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.ophtha.2019.03.048","article-title":"Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: a prospective case-control study","volume":"126","author":"Fan","year":"2019","journal-title":"Ophthalmology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3928\/23258160-20180129-07","article-title":"Outcomes of intravitreal bevacizumab and diode laser photocoagulation for treatment-warranted retinopathy of prematurity","volume":"49","author":"Chen","year":"2018","journal-title":"Ophthalmic Surg Lasers Imag Retina."},{"key":"B32","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ophtha.2020.11.012","article-title":"Neurodevelopmental outcomes after bevacizumab treatment for retinopathy of prematurity: a meta-analysis","volume":"128","author":"Tsai","year":"2021","journal-title":"Ophthalmology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.siny.2015.06.004","article-title":"Retinopathy of prematurity and neurodevelopmental disabilities in premature infants","volume":"20","author":"Beligere","year":"2015","journal-title":"Seminars Fetal Neonatal Med."},{"key":"B34","unstructured":"Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity (ROP1)"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.778585\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T05:59:56Z","timestamp":1644559196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.778585\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":34,"alternative-id":["10.3389\/fped.2022.778585"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.778585","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"article-number":"778585"}}